Skip to content

Study · Measured the body's own peptide · 2008

6 results

Downregulation of thymosin beta4 expression by androgen in prostate cancer LNCaP cells.

Iguchi K, Ito M, Usui S, Mizokami A, Namiki M, Hirano K

Journal of andrology3 Oct 2007Cited by 9 (Europe PMC)

PMID17916567 (opens in a new tab)DOI10.2164/jandrol.107.003608 (opens in a new tab)PepBankPUB-17916567
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Natural levels measured6

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01LabEndogenous levelIn vitro (cells)Mechanism

    In androgen-sensitive LNCaP prostate cancer cells, thymosin beta4 mRNA expression increased under androgen-deficient conditions.

    In plain wordsIn prostate cancer cells in the lab, the body's own thymosin beta4 mRNA rose when androgen was missing from the medium.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseThymosin beta4 mRNA in androgen-deficient medium
    Study

    humann: not reported in source

    LNCaP prostate cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Thymosin beta4 mRNA expression was increased in LNCaP cells in the androgen-deficient condition
    1 context sentence
    Summary · context
    The mRNA expression of thymosin beta4 was determined by real-time polymerase chain reaction analysis.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02LabEndogenous levelIn vitro (cells)Mechanism

    In LNCaP prostate cancer cells, dihydrotestosterone treatment decreased thymosin beta4 mRNA expression.

    In plain wordsIn prostate cancer cells in the lab, dihydrotestosterone lowered the body's own thymosin beta4 mRNA.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseThymosin beta4 mRNA after dihydrotestosterone
    Study

    humann: not reported in source

    LNCaP prostate cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    decreased by dihydrotestosterone treatment.
    1 context sentence
    Summary · context
    The mRNA expression of thymosin beta4 was determined by real-time polymerase chain reaction analysis.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  3. 03LabEndogenous levelIn vitro (cells)Mechanism

    In LNCaP prostate cancer cells, the androgen receptor antagonist bicalutamide inhibited thymosin beta4 expression in a dose-dependent manner.

    In plain wordsIn prostate cancer cells in the lab, bicalutamide lowered the body's own thymosin beta4 expression, more at higher doses.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseThymosin beta4 expression after bicalutamide
    Study

    humann: not reported in source

    LNCaP prostate cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Androgen receptor antagonist bicalutamide inhibited thymosin beta4 expression in a dose-dependent manner.
    1 context sentence
    Summary · context
    The mRNA expression of thymosin beta4 was determined by real-time polymerase chain reaction analysis.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  4. 04LabEndogenous levelIn vitro (cells)Mechanism

    In androgen receptor-negative PC-3 cells, no significant effects on thymosin beta4 gene expression were observed.

    In plain wordsIn prostate cancer cells without the androgen receptor, the body's own thymosin beta4 gene expression did not change significantly.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeThymosin beta4 expression in androgen receptor-negative PC-3 cells
    Study

    humann: not reported in source

    PC-3 prostate cancer cells (androgen receptor-negative)
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    In androgen receptor-negative PC-3 cells, no significant effects on thymosin beta4 gene expression were observed.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  5. 05LabEndogenous levelIn vitro (cells)Mechanism

    In LNCaP cells, the region between -83 bp and -46 bp of the thymosin beta4 gene was responsible for androgen regulation of its transcriptional activity.

    In plain wordsIn prostate cancer cells in the lab, a short stretch of the gene for the body's own thymosin beta4 controls how androgen changes its activity.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableThymosin beta4 promoter region responsible for androgen regulation
    Study

    humann: not reported in source

    LNCaP prostate cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    Responsible gene region
    −83 to −46 bp
    thymosin beta4 gene

    Source sentences

    Summary
    Deletion analysis revealed that the region between -83 bp and -46 bp of the thymosin beta4 gene is responsible for the regulation of the transcriptional activity by androgen.
    1 context sentence
    Summary · context
    The mRNA expression of thymosin beta4 was determined by real-time polymerase chain reaction analysis.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  6. 06LabEndogenous levelIn vitro (cells)Mechanism

    In LNCaP prostate cancer cells, androgen regulation of thymosin beta4 mRNA expression was due to transcriptional activation.

    In plain wordsIn prostate cancer cells in the lab, androgen changed the body's own thymosin beta4 mRNA by acting on the gene's activity.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableMechanism of androgen regulation of thymosin beta4 mRNA
    Study

    humann: not reported in source

    LNCaP prostate cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    The regulation of thymosin beta4 mRNA expression by androgen is due to the transcriptional activation.
    1 context sentence
    Summary · context
    The transcriptional activity of thymosin beta4 was measured by luciferase assay using reporter plasmid containing 5'-flanking region of thymosin beta4.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.